Our expert oncology teams meet periodically to discuss important developments in cancer management and explore innovative ways to advance clinical practice.

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel 

The Oncologist

15 June 2022

The Oncologist.jpg

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer

Clinical Breast Cancer 

21 August 2019

Clinical Breast Cancer.jpg

Use of Molecular Assays and Circulating Tumor DNA in Early Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group (GICTEG)

The Oncologist

2021

The Oncologist.jpg

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Breast Cancer Research and Treatment

20 November 2018

 Breast Cancer Research and Treatment.jpg

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)

Clinical Breast Cancer 

8 January 2020

Clinical Breast Cancer.jpg

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)
 

Breast Cancer Research and Treatment

5 January 2018

 Breast Cancer Research and Treatment.jpg

This expert team explores important oncology developments related to breast cancer management, with a emphasis on new findings and areas where guidance from established bodies, such as the National Comprehensive Cancer Network (NCCN) and the American Society for Clinical Oncology (ASCO), may be unresolved. 

The GICTEG is a group of expert oncology physicians and clinical researchers who have dedicated their careers to the treatment of patients with gastrointestinal cancer, with a particular emphasis on new findings in oncologist education. The goal is to elicit the group’s opinions on a given topic as it relates to their own clinical practices, and more importantly, how this might impact busy oncologists in the community setting, where gastrointestinal cancer is only one of many tumor types encountered.